A-A-0051878(DM)
12 March 1987
INTERIM COMMERCIAL ITEM DESCRIPTION
RANITIDINE HYDROCHLORIDE INJECTION
The General Services Administration has authorized the use of this Interim Commercial Item Description which was developed by the Defense Personnel Support Center, Directorate of Medical Materiel, DPSC-RST, 2800 South 20th Street, Philadelphia, PA 19101, based upon currently available technical information.
Salient characteristics:
Shall be Ranitidine Hydrochloride Injection.
All ingredients shall be of pharmaceutical grade.
Shall contain 25 mg of Ranitidine equivalent per ml, within the applicable assay limits.
Workmanship. The Injection shall be free from defects which detract from its appearance or impair its serviceability.
Unit. Vial (VI). One commercially available multiple-dose vial containing 10 ml, as specified, constitutes one unit.
Contractor certification. The contractor shall certify that the product offered meets the salient characteristics of this description and conforms to the producers’ own drawings, specifications, standards, and quality assurance practices. The Government reserves the right to require proof of such conformance prior to first delivery and thereafter as may be otherwise provided for under the provisions of the contract.
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
For Parts Inquires submit RFQ to Parts Hangar, Inc.
© Copyright 2015 Integrated Publishing, Inc.
A Service Disabled Veteran Owned Small Business